Introduction
Angiotensin-converting enzyme (ACE) inhibitors are a doubled-edged sword. They are recommended for patients with diabetic nephropathy and other forms of glomerular disease with proteinuria on the grounds that they can slow the decline of renal function in these conditions. 1 Outcome trials have shown cardiovascular benefits when ACE inhibitors are used to treat hypertension, heart failure, LV systolic dysfunction, coronary heart disease and stroke. [2] [3] [4] On the other hand, ACE inhibitors may lead to the loss of renal function in patients with bilateral renovascular disease, 5, 6 when co-administered with NSAIDs 7 or large doses of diuretics 8 and, when there is marked volume depletion. 9, 10 Studies of patients presenting with acute renal failure to renal units suggest that ACE inhibitors are implicated in 8% of cases. 9 Against this background, we wish to report three cases of severe acute renal failure in patients who developed intercurrent diarrhoeal illnesses while taking ACE inhibitors, together with the results of a survey to determine the frequency with which diarrhoea and vomiting are associated with acute renal failure in patients taking ACE inhibitors at the time of their admission as medical emergencies to a district general hospital.
Case reports

Case 1
A 54-year-old man was admitted in September 1999 with a 2-week history of diarrhoea on a background of chronic alcohol excess and hypertension. He had continued to take lisinopril, amlodipine and frusemide. On admission he looked well, and appeared alert and orientated. Heart rate was 80 per min with blood pressure was 95/72 mmHg. Initial investigations showed serum sodium 125 mol/l, potassium 4.3 mmol/l, urea 47.3 mmol/l and creatinine 1594 mmol/l. His drugs were stopped and he was treated with intravenous fluids. He required 7 l of fluid in the first 24 h before a diuresis occurred. His serum biochemistry returned to normal over a period of 5 days and he did not require dialysis ( Figure 1 , case 1).
Case 2
A 66-year-old woman was referred to the hospital in October 1999 with a 10-day history of diarrhoea and vomiting. She gave a past history of chronic obstructive pulmonary disease and myocardial infarction for which she was taking captopril and aspirin. She again looked well and did not appear shocked, with heart rate 70 per min and blood pressure 106/64 mmHg. Serum biochemistry showed sodium 128 mmol/l, potassium 4.2 mmol/l, urea 56.2 mmol/l and creatinine 959 mmol/l. Treatment by withdrawal of captopril and over 7 l of intravenous fluid in the first 48 h caused a fall in her urea and creatinine, which returned to normal over the course of the next 4 days without the need for dialysis ( Figure 1 , case 2).
Case 3
A 48-year-old man developed diarrhoea 4 days after returning from a holiday in the Greek Islands in July 2000. He gave a past history of hypertension and gout for which he was taking irbesartan 75 mg od, atenolol 100 mg od, allopurinol 100 mg od and aspirin 75 mg od. He was haemodynamically stable when first seen with heart rate 60 per min and blood pressure 110/49 mmHg. Results of investigations included sodium 125 mmol/l, potassium 3.7 mmol/l, urea 23.7 mmol/l and creatinine 688 mmol/l. Salmonella group B was isolated from his stool. Treatment consisted of ciproxin, withdrawal of irbesartan and atenolol plus intravenous fluid. Over 10 l were given during the course of the first 30 h of hospital admission. Renal function returned to normal over the course of the next 10 days with urea 3.3 and creatinine 123 mmol/l at the time of discharge ( Figure 1 , case 3).
Retrospective cohort study By linking the hospital's admissions records with biochemistry reports electronically, we were able to identify 89 patients whose serum creatinine was X200 mmol/l at the time of their admission. Nine were regular dialysis patients. The casenotes of the remaining 80 patients were retrieved.
In all, 30 of 80 patients (37.5%) were taking an ACE inhibitor (n ¼ 29) or an angiotensin receptor blocker (n ¼ 1) at the time of admission. These patients were elderly (average age 70 years) with multiple comorbidities including heart failure (23), coronary heart disease (20), diabetes mellitus (17), hypertension (14) and renal disease (12) . Several patients had more than one pathology. The ACE inhibitors were lisinopril (12), ramipril (7), enalapril (5), captopril (4) and perindopril (1) . We included the only patient who was taking an angiotensin receptor blocker (losartan) in the ACE inhibitor group on the grounds that the renal effects of angiotensin receptor blockers and ACE inhibitors are similar. 11 Of the 30 patients, six (20%) patients on an ACE inhibitor gave a history of diarrhoea and/ or vomiting which is likely to have been the cause of their acute deterioration in renal function: median creatinine in this group was 135 (range 111-209) mmol/l before admission, 292 (216-724) mmol/l when first seen in hospital and 134 (94-219) mmol/l during follow-up after withdrawal of the drug and fluid replacement ( Table 1 ). The remaining 24 ACE inhibitor patients were a heterogeneous group. In all, 19 had evidence of reduced renal perfusion including six who were taking large doses of ACE inhibitors and acute renal failure C Stirling et al diuretics (arbitrarily frusemide X120 mg per day or bumetanide X3 mg per day) in the absence of any other explanation for a deterioration in renal function; seven with clinical and radiological evidence of heart failure; three who were septic and three who were taking NSAIDs. Five ACE inhibitor patients had no clinical evidence of reduced renal perfusion. None of the ACE inhibitor patients were known to have or were investigated to exclude the possibility of renovascular disease (Figure 2) . In order to test the hypothesis that diarrhoea and vomiting severe enough to require hospital admission may pose a particular threat for patients taking ACE inhibitors, we compared the creatinine profiles of the six diarrhoea and vomiting patients (Group A) with those of two other groups of patients who survived to leave hospital and had measurement of serum creatinine before, during and after admission: ACE inhibitor patients with other causes of reduced renal perfusion (Group B: 16 of 19 patients had a full set of measurements) and patients with reduced renal perfusion who were not taking ACE inhibitors (Group C: 25 of 34 patients had a full set of measurements). Medians before, during and after admission, and the medians for duringÀbefore and afterÀbefore were reported. The median differences and two sample two-sided Wilcoxon rank-sum test P-values were calculated for the comparisons of Groups A vs B, A vs C, and then for Group A against Groups B and C combined. All analyses were performed using SAS 8.2 for Windows and Minitab 13.0 for Windows. No adjustment was made for multiple comparisons. Table 1 shows that the ACE inhibitor, diarrhoea and vomiting group had a greater rise in their creatinine from baseline and a greater fall in creatinine with treatment than the other two groups, although these differences did not achieve statistical significance.
Discussion
Acute renal failure is a recognised complication of ACE inhibitors both in hypertension and heart failure. 10 A proportion of such patients will be found on further investigation to have bilateral renovascular disease or stenosis in a solitary kidney. 11 Elevation of serum creatinine can also occur if renal perfusion pressure falls for any reason in patients taking ACE inhibitors. This can result from an increase in diuretic therapy, co-prescription of an NSAID or the development of volume depletion from a nondiuretic induced cause such as gastroenteritis. 12 Decline in renal function occurs because of altered renal autoregulation: as renal perfusion pressure falls, the glomerular afferent arteriole dilates under the influence of prostaglandins. This is followed by constriction of the efferent arteriole as a result of intrarenal angiotensin II, in an attempt to maintain glomerular capillary pressure. 13 If efferent vasoconstriction is blocked by the reduction in angiotensin II caused by ACE inhibition, then autoregulation cannot occur and glomerular capillary pressure and subsequently glomerular filtration rate falls. This mechanism has been recognised before in patients with fluid losses who continue to take ACE inhibitors and has led to acute renal failure, previously associated with haemodynamic collapse. 14, 15 Another explanation for the observation that patients with reduced renal perfusion have a greater rise in serum creatinine if they are taking an ACE inhibitor may relate to the known effects of ACE inhibitors on the sympathetic and parasympathetic nervous systems. 16, 17 Patients taking ACE inhibitors Group A=six ACE inhibitor patients who developed acute renal failure during an intercurrent illness characterised by diarrhoea and/ or vomiting; Group B=16 ACE inhibitor patients with other causes of reduced renal perfusion; Group C=25 patients with reduced renal perfusion in absence of ACE inhibitor. P-values for comparison A vs B, A vs C and A vs B+C were 0.08-0.88.
ACE inhibitors and acute renal failure C Stirling et al who develop reduced renal perfusion for any reason may be less likely to mount a sympathetic response to volume depletion, that is, tachycardia and sweating, which would normally alert them to the fact that they were unwell, because ACE inhibitors not only block the sympathetic nervous system but also increase vagal tone. 16, 17 This could well account for the observation in our study that patients with severe volume depletion, perhaps particularly diarrhoea and vomiting, tend to present later and with more advanced degrees of renal failure if they are also taking an ACE inhibitor.
The first three cases of acute renal failure described in our report, and the six patients with diarrhoea and/or vomiting in our cohort study, were clearly dry but not profoundly hypotensive and certainly not shocked. The mechanism of their acute renal failure is likely to be the same as that reported by previous authors, and the lesson we believe is worthy of repitition. This is, that patients on ACE inhibitors who develop vomiting or diarrhoea are at risk of a reversible rise in serum urea and creatinine, sometimes amounting to severe acute renal failure. Our cohort study suggests this may be more severe with diarrhoea and vomiting than with other causes of reduced renal perfusion and that a district general hospital serving a population of 150 000 might expect to see such a problem arising approximately once a month.
Analysis of the drug information available to patients and their General Practitioner supports the view that the potential for this complication to occur is not widely appreciated. A total of 11 ACE inhibitors are currently licensed for use in the UK. The patient information literature that accompanies each prescription of these drugs lists diarrhoea as a side effect of ACE inhibition (9/11) and indicates that volume depletion may lead to exaggerated falls in pressure at the start of therapy (11/11) but gives no advice for patients who develop diarrhoea and vomiting while on therapy (0/11). Review of the information given to doctors in the British National Formulary reveals a similar picture: diarrhoea is listed as a side effect of ACE inhibitors (11/11), caution should be exercised if patients are volume deplete at the start of therapy (11/11) although no advice is given for patients who develop diarrhoea and vomiting while on therapy (0/11).
It has recently been reported that up to two-thirds of patients who start an ACE inhibitor did not have their renal function checked thereafter in general practice, 18 highlighting the need for guidelines for monitoring renal function in patients on ACE inhibitors. Many authorities recommend that urea and electrolytes are checked at 1 week and 1 month on the grounds that if creatinine has not risen by 1 month it is unlikely to do so thereafter. We would further recommend that patients on an ACE inhibitor should be warned of the possibility of volume depletion and reversible renal impairment during a diarrhoeal illness, and advised to contact their general practitioner in the event of such fluid losses. We know of no trial evidence that will help the general practitioner determine the next step but suggest that clinical circumstance should dictate the course of action. For most patients, it may be sufficient to omit concomitant diuretic therapy for a few days. For those who appear less well, it might be safer to measure renal function, stop both ACE inhibitor and diuretic temporarily and increase oral intake until the diarrhoeal illness has resolved.
